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Abstract
Liver cancer is a poor prognosis cancer with limited treatment options. To develop a new
therapeutic approach, we derived HCC cells from a known model of murine hepatocellular
carcinoma (HCC). We treated adiponectin (APN) knock-out mice with the carcinogen
diethylnitrosamine, and the resulting tumors were 7-fold larger than wild-type controls.
Tumors were disassociated from both genotypes and their growth characteristics evaluated.
A52 cells from APN KO mice had the most robust growth in vitro and in vivo, and presented
with pathology similar to the parental tumor. All primary tumors and cell lines exhibited activ-
ity of the mammalian target of Rapamycin (mTOR) and Src pathways. Subsequent combi-
natorial treatment, with the mTOR inhibitor Rapamycin and the Src inhibitor Dasatinib
reduced A52 HCC growth 29-fold in vivo. Through protein and histological analyzes we
observed activation of these pathways in human HCC, suggesting that targeting both
mTOR and Src may be a novel approach for the treatment of HCC.
Introduction
Liver cancer (hepatocellular cancer [HCC]), the fifth commonest in terms of cancer incidence
and the second leading cause of cancer related deaths worldwide, is a poor prognosis cancer
[1]. The major risk factors for HCC are hepatitis B virus (HBV) and hepatitis C virus (HCV)
infection, and excessive alcohol intake that promote fibrosis and cirrhosis, and ultimately
oncogenic transformation. However, in the last 3 decades, rising rates of obesity and the meta-
bolic syndrome have led to dramatic increases in HCC related to non-alcoholic fatty liver dis-
ease (NAFLD) and its inflammatory form non alcoholic steatohepatitis (NASH). HCC arising
in this context can develop in the absence of cirrhosis [2]. Over 1 billion people worldwide
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have NAFLD [3] and thus it is to be expected that NASH HCC will become the most common
cause for liver transplantation and an increasing cause of morbidity [4]. The therapeutic
options for all forms of HCC are limited with just 2 approved agents (Sorafenib and Regorafe-
nib) that prolong life by a median of just 10–12 weeks [5–7]. Hence new therapeutic
approaches based on an understanding of disease pathogenesis and molecular phenotype are
urgently required.
A pathway that has been previously targeted is the mammalian target of Rapamycin
(mTOR). mTOR is present in two different complexes mTORC1 and mTORC2; only
mTORC1 is sensitive to Rapamycin. Active and phosphorylated mTOR phosphorylates 4E-
binding protein (4E-BP1) and p70S6K translation initiation factors that are necessary for cap-
dependent mRNA translation. This in turn increases the synthesis of numerous proteins
required for cell cycle progression, angiogenesis, cell proliferation and growth. mTOR activity
is also regulated by a number of oncoproteins and tumor suppressors, including AMP-acti-
vated protein kinase (AMPK), protein kinase B (AKT) and more recently, the non receptor
tyrosine kinase (non-RTK) Src [8, 9]. Importantly, studies have shown that mTOR is upregu-
lated in HCC [10, 11] and this has led to clinical trials of mTOR inhibitors or their combina-
tion with other drugs. However, the results have been uninspiring and offer no alternative to
current therapeutic practices [12–14]. Considering that mTOR sits at the intersection of a
number of signaling pathways and the diverse clinical and molecular heterogeneity of HCC, it
is highly plausible that a myriad of feedback mechanisms, for example the sustained activation
of AKT, can over-ride the specificity of a mTOR inhibitor. Thus, to treat HCC, a combinatorial
approach may be required predicated on understanding the molecular phenotype of tumors as
already shown for melanoma [15].
Another difficulty in the field is that the majority of HCC tumor models are cell lines
derived from human HCCs. Although this a positive in representing the genetics and signaling
pathways of human HCC, studies in vivo must then use immune compromised mice, that then
leads to possible differences in responses from the host, and lacks the representative pathology
of human disease. Thus, any advancement in available models could possibly lead to better
therapeutic approaches. To address these issues concerning murine models and mTOR
directed therapy, we chose to focus on the adipokine, adiponectin, whose serum levels are par-
adoxically reduced as body mass index (BMI) increases, and parallels dysregulated lipogenesis,
liver fibrosis and hepatic inflammation and fatty liver disease [16, 17]. In genetic models, low
serum APN can promote breast and colon cancer development through angiogenic mecha-
nisms and by modulating the AMPK-activated protein kinase (AMPK)/mammalian target of
Rapamycin (mTOR) pathway [18, 19]. In mice APN absence promotes liver tumor formation
in mice fed a choline-deficient diet L-amino acid-defined diet or treated with the carcinogen
azoxymethane [20, 21]. We treated APN null mice with diethylnitrosamine (DEN) and
observed larger HCCs versus wild-type, and derived A52 cells from an APN KO tumor. Subse-
quent combinatorial inhibition of mTOR and Src with Rapamycin and Dasatinib dramatically
reduced A52 tumor growth and importantly, we observed activity of the mTOR and Src path-
ways in human HCC. These data support the use of Dasatinib to synergize with the action of
mTOR inhibitors to treat HCC.
Materials and methods
Animal studies
APN KO mice were sourced from the Matsuzawa lab [22] and bred onto the in house C57B/
6 strain for 6 generations. HCC was induced at P15 with a single intraperitoneal injection of
diethylnitrosamine 25 mg/kg (DEN; Sigma Aldrich). Mice were kept in a temperature-
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controlled facility with 12-hour light/dark cycles and were fed a standard rodent chow diet
with water ad libitium. Animal coat texture and vital signs were examined three times per
week and at experiment end euthanized by carbon dioxide inhalation 9 months after injec-
tion and examined for metastases. The livers were weighed and macroscopically assessed
for tumor growth. Tumor incidence (>0.5mm) and total tumor volume were calculated
(volume = width2 x length/2). Tumour cell injections were performed on mice anesthetized
with ketamine (60mg/kg body weight) and xylazine (100mg/kg body weight). Animal
experimental protocols were approved by the Western Sydney Area Health Service Animal
Ethics Committee.
Histology, immunohistochemistry, and image analysis
Murine tissue was fixed in 4% paraformaldehyde in PBS overnight, dehydrated, and embedded
in paraffin. Sections were cut at 10 μm and stained with H&E and pathologic evaluation was
performed independently by PB and TR. The other half was snap-frozen in liquid nitrogen
and sectioned frozen at 7 μm for immunohistochemical analysis. Formalin-Fixed paraffin
embedded human and mouse samples were stained using the Bond Polymer Refine Detection
kit on the Bond Max autostainer (Leica) with antibodies against Ki67 (ab15580; abcam), p-
mTOR (2976S; Cell Signaling) and p-4E-BP1 (236B4; Cell Signaling). Frozen sections were
fixed in ice-cold acetone or 4% paraformaldehyde in PBS for 10 min and stained with phos-
hpo-histone H3 (ser10; 9701; Cell Signaling) and TUNEL (Roche), respectively and counter-
stained with DAPI. Human HCC tumors were sourced from the Westmead Liver Clinic and
the Leuven Pathology tumor bank; non-cirrhotic liver tissue surrounding a colorectal metasta-
sis was used as a control, and approved by the Westmead Human Ethics Committee and Ethi-
cal Committee UZ Leuven. H & E slides were scanned with a NanoZoomer 2.0-HT and
images prepared in Photoshop. Immunofluoroescent images were taken using a Spot camera
(Diagnostic Incorporated) on a Zeiss Axiovert 405M microscope and the density calculated
with ImageJ software.
RNA isolation, quantitative real time RT-PCR and serum analyses
Total cellular RNA was extracted from liver and tumor tissue, treated with DNase and resus-
pended in RNase free water, complementary DNA synthesized and real-time polymerase
chain reaction carried out using specific primers for CD68; forward TGACCTGCTCTCTCTA
AGGCTACA and reverse TCACGGTTGCAAGAGAAACATG; IL-6; forward TAGTCCTTCCTA
CCCCAATTT and reverse TTGGTCCTTAGCCACTCCTTC, and TNFα forward TCTTCTCA
TTCCTGCTTGTGG and reverse CACCCCGAAGTTCAGTAGACA and normalized against
GAPDH, forward GTCGTGGATCTGACGTGCC and reverse TGCCTGCTTCACCACCTTC. The
serum markers for glucagon, insulin, leptin, interleukin-6 (IL-6) and tumor necrosis factor-α
(TNFα) were measured from the serum of WT and APN KO mice using the Luminex200 ana-
lyser according to the manufacturer’s instructions. Aspartate transaminase (AST) and alanine
transaminase (ALT) were measured through the in-house pathology service.
Protein extraction and western blotting
Frozen pairs of HBV and HCV human non-tumor and tumor, and 3 primary NASH HCCs
were sourced from the Westmead Liver Clinic and approved by the Westmead Hospital
Human Ethics Committee. Total protein extracts from murine and human tumor tissue were
subjected to immunoblotting as previously described [23]. Antibodies for AMPK (#2532),
phospho-AMPK (Thr172; #2535), Akt (#9272), p-Akt (Ser 473; #4051), mTOR (#2972), p-
mTOR (Ser2448; #2971, 4E-BP1 (#9644), p-4E-BP1 (Thr70 and Ser65; #9455), p70S6-kinase
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(#9202), p-p70S6-kinase (Thr421/Ser424; #9204), Src (#2108), p-Src (Tyr416; #2101), AFP
(#3903), JNK (#9252), p-JNK (Thr183/Tyr185; #9255) and PCNA (#2586) were from Cell Sig-
naling. Anti-β actin (A2228) antibodies were from Sigma Aldrich, and anti-albumin (NB600-
41532) was from Novus Biologicals.
Primary tumor experiments
Liver tumors were cultured as previously described by He et al., [24]. Briefly, they were minced
with surgical razor blades and digested at 37˚C for one hour in 10 mM HEPES, pH 7.4 and
0.25% w/v collagenase B in Hank’s BSS with Ca2+ and Mg2+, filtered through a 100 μm cell
strainer, preplated and cultured in 20% FCS in DMEM high glucose containing 0.01g/l insulin,
0.01 g/L hydrocortisone hemisuccinate, 1% penicillin-streptamycin, 0.25 mg/L amphotericin
B, 1mM phenobarbital and 20 μg/L EGF (Invitrogen or Sigma Aldrich). Cells were not used
past passage 8. In vitro: In 96-well plates 10,000 cells were plated per well and once 40–50%
confluent, Rapamycin and Dasatinib supplied for 24 hours at the indicated concentrations;
proliferation was assessed using a BrdU ELISA kit (Roche; performed in quadruplicate three
times). In vivo: 2.5 x 106 cells in 150 μL Matrigel/PBS were injected bilaterally and subcutane-
ously into the back flanks of 8–12 week old male wild-type mice. Tumor growth was moni-
tored 3 times per week by measurement with calipers. For treatment, tumors were allowed to
either reach approximately 50 mm3 or 500 mm3 and the mice then treated daily by oral gavage:
Rapamycin 7.5 mg/kg and Dasatinib 30 mg/kg (Selleckchem) diluted in 5.1% polyethylene gly-
col and 5.1% Tween-80.
Statistical analysis
All values are reported as mean ± standard error of the mean. Unless otherwise specified in the
figure legend, statistical significance was determined using a one-way ANOVA for experi-
ments with two or more groups, and Bonferroni post-testing, with p-values <0.05, 0.01, 0.001
and 0.0001 considered to be significant and represented with (�), (��), (���) and (����), respec-
tively. The students t-test was employed for statistical comparison between two groups
(Graphpad Prism).
Results
APN KO mice have larger HCCs
HCC was induced in APN KO mice and after 9 months the mice had significantly larger
HCCs. The tumors were 6.8-fold larger and total tumor volume was 207 ± 101 mm3 versus
30.2 ± 15.0 mm3 in the KO mice versus WT controls (p = 0.0331; Fig 1A–1C). Liver to body
weight ratios increased in APN KO (APN KO: 5.51 ± 0.277%, n = 21 versus WT: 4.47 ±
0.101%, n = 22; p = 0.0009, Fig 1D), and between groups there was no difference in tumor inci-
dence (Fig 1E). Analyses revealed in WT, 12 pre-neoplastic foci and 23 liver carcinomas, and
in the APN KO, 14 pre-neoplastic lesions and 32 carcinomas. Histology analyses illustrated
similar pathology in non-tumor regions, and no remarkable change was noted in pathology
between WT and APN KO tumors. Inclusion bodies were observed in the tumors of both
genotypes and examples of neoplastic pathology at low and high-power magnification are
illustrated (Fig 1F–1I). No lung metastases were recorded in either genotype and Ki67 staining
was increased in APN KO versus WT tumors by 1.4-fold (p = 0.0044; S1A–S1C Fig). There
was no apparent collagen deposition in either genotype (S1D and S1E Fig) and no significant
change in metabolic and inflammatory markers (S2A–S2J Fig). These data suggest that the
absence of APN promotes development of larger and more aggressive liver cancers.
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Establishment of APN KO primary tumor cell lines
APN can modulate HCC tumor cell behavior through specific signaling pathways [25]. Hence,
to determine any pro-proliferative signals we undertook western blots and densitometry of
phosphorylated and total signaling proteins. And we saw unaltered protein expression of p-
mTOR, p-AMPK, p-AKT, p-Src and p-JNK between genotypes in the tumors (Fig 1J–1N; and
S2K and S2L Fig, S3 Fig).
Fig 1. APN KO mice have larger HCCs. Adiponectin KO male mice 9 months post-DEN have A, liver tumors 7 times
larger than wild type male mice. B-C, Representative images of WT and APN KO livers 9 months after DEN treatment.
D, APN KO mice have increased liver body weight ratio. E, Similar tumor incidence between WT and APN KO mice.
F-I, Representative histology from WT (F, G) and APN KO (H, I) tumors (scale bars 500 and 50 μM). J-N, Western
blot and densitometry analyses of WT and APN KO tumors show unaltered mTOR, AMPK, AKT and Src signaling.
https://doi.org/10.1371/journal.pone.0212860.g001
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In the HCC field there are limited syngeneic cellular models of murine HCC that can be
propagated in vitro and in vivo. We therefore generated primary cultures of WT and APN KO
tumor cells and developed a transplantable model system to trial therapeutic strategies. West-
ern blot of the primary culture cell lysates revealed expression of p-mTOR, mTOR, p-Src, Src,
PCNA, albumin and α-fetal protein (AFP) (Fig 2A; S4 Fig) in WT and APN KO cells. Their
epithelial nature was confirmed by immunofluorescence for Keratin 8 (K8) and Pancytokera-
tin (PK; A52 cultures; Fig 2B). Evaluation of growth revealed that WT tumor cells grew poorly
in vitro and in vivo compared to APN KO tumor cells, and only A52 cells had robust growth in
vitro and in vivo (Fig 2C). Significantly, the examination of the pathology of the primary and
transplanted A52 cells revealed similar morphological similarities (Fig 3). On this basis, we
chose to use A52 cells for our remaining studies.
Fig 2. Primary cell characterization. As per the materials and methods, tumors were isolated from mice and cultured.
A, Primary murine hepatocytes were used as controls (Mu). Western blot revealed the primary cultures of APN KO
A51, A48, A50 and A52 and WT C53, C54 and C55 cells to express p-mTOR, mTOR, p-Src, Src, PCNA, albumin and
AFP. B, Immunofluorescence for K8 and pan-cytokeratin (PK) confirmed that A52 cells were epithelial (Scale bar
20 μM). C, Table showing in vitro and in vivo growth characteristics of WT and APN KO primary cultures. Scale of
growth (+ to ++++).
https://doi.org/10.1371/journal.pone.0212860.g002
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Combinatorial treatment with Rapamycin and Dasatinib restricts HCC
growth
Given that the APN KO and WT HCCs and primary cultures express abundant phosphory-
lated mTOR and Src we chose to target these pathways. To test the mTOR pathway we treated
A52 tumors with the mTOR inhibitor Rapamycin and it effectively restricted tumour growth
(p = 0.0001). In discerning signaling differences, we observed increased Src phosphorylation
in the Rapamycin treated tumor cohort (p<0.05) (Fig 4A–4C). Previous data has shown that
mTOR inhibitors in conjunction with Src inhibitors are more efficacious in treating various
cancer types, we therefore considered whether this mechanism was functional in A52 cells [9,
26]. To confirm the action of each drug on mTOR and Src phosphorylation, we treated A52
cells with increasing concentrations of Rapamycin or Dasatinib and performed western blots
Fig 3. Similar pathology between parental and transplanted A52 tumors. H& E sections of A and B, The original
APN KO A52 tumor, and C and D, Transplanted A52 tumor. Scale bars: A and C 250 μm; and B and D, 100 μm.
https://doi.org/10.1371/journal.pone.0212860.g003
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for phosphorylated and total mTOR, 4E-BP1, p70S6K, Src and AKT. Compared to control
cells, Rapamycin treatment alone had no effect on p-mTOR, p-Src and p-AKT, but reduced p-
4E-BP1 and p-p70S6K levels. Dasatinib treatment did not decrease p-mTOR, p-4E-BP1, p-
Fig 4. Limiting mTOR and Src activity restricts HCC growth. A, A52 subcutaneous tumor growth curves when
treated with Rapamycin (Rapa; n = 8) and versus placebo (n = 6). Linear regression demonstrated that Rapamycin
(p<0.0001) significantly reduced tumour growth. B-C, Western blotting showed a significant increase in p-Src/Src in
the Rapamycin treated group (�p<0.05). D, Dose-dependent signaling analyses showed that Rapamycin (0–300 nM)
reduced 4E-BP1 and p70S6K phosphorylation and Dasatinib (0–300 nM) reduced Src phosphorylation. The
combination of Rapamycin and Dasatinib reduced 4E-BP1, p70S6K, Src and AKT phosphorylation. ß-actin loading
control. E, Growth curves of 500 mm3 subcutaneous tumors treated with Dasatinib, Rapamycin, or Rapamycin
+ Dasatinib (n = 8, all groups). Linear regression analyses showed that Dasatinib or Rapamycin had no effect on tumor
growth kinetics. The combination of Rapamycin + Dasatinib reduced tumor growth kinetics (p = 0.0012). F, Fold
change in tumor volume per tumor for the treatment period Day 0–15 was determined by one-way ANOVA and
Bonferroni’s multiple comparisons test. Versus placebo, Dasatinib or Rapamycin had no effect, and Rapamycin
+ Dasatinib significantly increased the fold-reduction in tumor volume (p = 0.029).
https://doi.org/10.1371/journal.pone.0212860.g004
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p70S6K and AKT levels, but did reduce p-Src levels. The combination of Rapamycin and Dasa-
tinib had no effect on p-mTOR, but greatly impeded the phosphorylation of 4E-BP1, p70S6K,
Src and AKT (Fig 4D; S5 Fig).
Given that the application of both Rapamycin and Dasatinib had a greater inhibitory effect
on mTOR and Src activity than either alone, we tested their ability to restrict A52 HCC growth
in vivo. To model HCC growth as in patients, the tumors were allowed to reach 500 mm3 and
then treated with each drug alone, or in combination. Analyses of tumor growth rates by linear
regression revealed that compared to the placebo group, Dasatinib had no effect on tumor
growth and Rapamycin reduced tumor volume, but this was not significant. In contrast, the
combination of Rapamycin and Dasatinib significantly decreased tumor growth (p = 0.0012;
Fig 4E) and reduced the fold volume change per tumor by 29-fold (p = 0.029; Fig 4F), and this
was significantly different when compared to singular Rapamycin (p = 0.037) and Dasatinib
(p = 0.033) treatments.
The dramatic decrease in tumor load we observed could be accounted for in part by a
reduction in tumor cell proliferation and an increase in apoptosis, as determined by quantita-
tive immunofluorescence of phosphorylated histone H3 (PH3H) and TUNEL, respectively
(Fig 5A and 5B; S6 Fig). Compared to placebo, Dasatinib reduced tumor cell proliferation
1.5-fold (p< 0.01) and Rapamycin 2.5-fold (p< 0.0001), while Dasatinib or Rapamycin did
not induce tumor cell apoptosis. In contrast, the combination of Rapamycin and Dasatinib
reduced HCC proliferation 9.8-fold and increased apoptosis 14.7-fold (p<0.0001 for both).
Unexpectedly, in the tumors, unlike cells in culture, mTOR phosphorylation was better inhib-
ited (p<0.05; for all) and 4E-BP1 phosphorylation was only inhibited in the co-treatment
group. p70S6K phosphorylation was limited by all three therapeutic approaches (p<0.05 for
Rapamycin or Dasatinib, and p<0.01 for Rapamycin plus Dasatinib). Src and AKT phosphory-
lation was reduced only in the combinatorial cohort (p< 0.05, Fig 5C and 5D; S7 Fig). Given
these data, we examined tumor pathology and observed that placebo, Rapamycin and Dasati-
nib groups had aggressive HCC pathology while the combinatorial treated tumors were
necrotic (Fig 5E). These data suggest that the effects of Rapamycin and Dasatinib restricts
mTOR and Src signaling leading to reduced A52 tumor growth.
Human translational potential
To determine if the signaling pathways observed in our animal model are present in human
HCC we investigated the expression of the mTOR and Src pathways in human tumor tissues
(Westmead Liver Clinic). In six primary pairs of HBV (n = 3) and HCV (n = 3) tumor and
non-tumor tissues we observed in the tumors the expression of p-p70S6K (4 from 6), p-
4E-BP1 (6 from 6), and p-Src (5 from 6) (Fig 6A). In NASH HCC tumors the mTOR pathway
was present in one sample and p-Src in 2 (Fig 6B, S8 Fig). To extend our studies, 10 HCV and
10 NASH HCC samples (Leuven Histopathology Tumor Bank) were examined histologically
for p-4E-BP1 and p-mTOR expression. For HCV HCC, 5 from 10 expressed p-mTOR and 6
from 10 were p-4E-BP1 positive, and for the NASH HCC group, 9 from 10 expressed p-mTOR
and 8 from 10 were p-4E-BP1 positive (Fig 6C). These data suggest that active mTOR and Src
signaling is a feature of some human HCCs and their combinatorial targeting may hold prom-
ise as a mechanism-based therapeutic approach to treat HCC.
Discussion
Due to late detection, limited resection options and therapeutics, liver cancer is a poorly
treated cancer. Moreover, it is expected that the already high and increasing worldwide rates
of overweightness and obesity will translate into increased HCC incidence [27]. Furthermore,
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this is compounded as the search for new therapeutics is restricted by the limitation of trans-
plantable models that resemble human disease and the use of genetic models that are
Fig 5. Analyses of tissues after drug treatment. A, Histology for phospho-histone H3 (P3H3; n = 4–6 for each group)
showed that the Dasatinib (Dasat), Rapamycin (Rapa) and Rapamycin + Dasatinib treatments successively reduced
tumor cell proliferation and increased apoptosis. Proliferation: control versus Dasatinib (p = 0.01); Placebo versus
Rapamycin (p = 0.0001); control versus Rapamycin + Dasatinib, (p = 0.0001); Dasatinib versus Rapamycin (p = 0.05);
Dasatinib versus Rapamycin + Dasatinib (p = 0.0001) and Rapamycin versus Rapamycin + Dasatinib (p = 0.05). B,
Histology by TUNEL (n = 4–6 for each group) showed that compared to control, only Rapamycin + Dasatinib
treatment increased tumor cell apoptosis (p = 0.0001), was significantly greater than that observed for Dasatinib
(p = 0.0001) and Rapamycin (p = 0.01) treatments. C-D, Representative western blot densitometry analyses showing
that compared to control, a small but significant reduction in p-mTOR/mTOR density in all groups (p = 0.05); an
increase in p-4E-BP1/4E-BP1 for Rapamycin (p = 0.05) and no significant change in Dasatinib or Rapamycin
+ Dasatinib; reduced p-p70S6K/p70S6K density for all groups (p = 0.05 for Rapamycin or Dasatinib, and p = 0.01 for
Rapamycin + Dasatinib); and reduced p-Src/Src and p-AKT/AKT for control versus Rapamycin + Dasatinib only
(p = 0.05). E, Tumor pathology was necrotic in the Rapamycin + Dasatinib treatment group.
https://doi.org/10.1371/journal.pone.0212860.g005
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unacceptably long and expensive. To address this, we used APN KO mice and developed a
transplantable syngeneic model and validated its potential using known inhibitors, and then
performed a comparative signaling analyses of human HCC. Significantly, we find that A52
tumors when treated with the combination of Rapamycin and Dasatinib are dramatically
reduced in size and we show that these pathways are present in a subset of human HCC driven
by HBV, HCV and NASH.
mTOR expression has been extensively studied in HCC, but its inhibition by small mole-
cules has been shown to be an ineffective way to treat HCC. By example, trials with the mTOR
inhibitor Everolimus alone or when combined with sorafenib offered no survival advantage
compared to placebo in patients with advanced HCC [12, 14]. In tumors of the colon, prostate
and breast, Src is highly expressed and is associated with aggressive migratory cell behavior,
differentiation and recently metabolism [28–30]. In HCC, Src is expressed in approximately
50% of human tumors derived from either HBV or HCV [31], but few studies have explored
Src’s role in other molecular pathways such as mTOR or the utility of specific Src inhibitors to
restrict HCC growth.
A major reason for the failure of mTOR targeted therapies is feedback activation of the
strong and pro-survival AKT and the proto-oncoprotein Src. Emerging data shows that non-
RTKs like Src and other Src-kinases can support PI3K/AKT/mTOR signaling by modulating
cell-cycle progression and survival [32, 33], and in turn mediate RTK signaling that activates
Fig 6. The mTOR and Src pathways are expressed in human HCC. A, Western blots of human hepatic non-tumor
and tumor from HBV and HCV HCCs illustrate expression of p-p70S6K, p-4E-BP1 and p-Src; and B, in human
NASH HCCs. C, Representative histology of human NASH HCC and HCV-HCC illustrating specific staining for p-
mTOR and p-4E-BP1.
https://doi.org/10.1371/journal.pone.0212860.g006
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mTOR [34]. Additionally, Src can interact and activate AKT [35], and in other models inde-
pendent of AKT, activate the mTORC1 complex [36], and separately modulate p70S6K activity
[37]. Thus, there are potentially multiple levels for crosstalk between the Src and mTOR path-
ways. Studies in breast cancer and human non-small cell lung cancer (NSCLC) have shown
that Rapamycin maintains AKT and Src activity. The combination of Rapamycin and Dasati-
nib induced tumor regression in a genetic mouse mammary tumor virus-polyomer middle T
antigen model [9], and in NSCLC suppressed Src and AKT phosphorylation [26]. In line with
our expectations, we observed that Rapamycin failed to reduce tumor growth and there was
no effect on AKT and Src activity. Similarly, Src’s action in vivo was akin to that of the placebo
and there was no effect on AKT phosphorylation. In direct contrast, the use of both inhibitors
in vivo further reduced mTOR and p70S6K phosphorylation and strikingly reduced Src and
AKT phosphorylation. Importantly, the drug combination altered tumor pathology, increased
necrosis and reduced tumor cell proliferation, and resulted in cancers that were 29-fold smaller
than placebo and had regression of the aggressive phenotype. This study is the first to show in
a pre-clinical HCC model the efficacy of using both Rapamycin and Dasatinib to treat and
restrict HCC growth.
To support our data, we examined mTOR and Src pathway activity in a small cohort of tis-
sue samples from HBV, HCV and NASH HCC. In frozen tissues of HBV and HCV HCC both
pathways are expressed, and in the three NASH HCCs the mTOR pathway is less active, but
this could just be a function of the time of resection to being snap frozen, while histological the
mTOR pathway was expressed, and is in agreement with a previous study examining p-mTOR
and p-4E-BP1 expression in NASH HCC [38]. Previous studies have histologically shown the
expression of Src and p-Src in HCC types [31]. We attempted similar studies with three com-
mercial antibodies against p-Src and this did not parallel Src staining to similar cellular struc-
tures. Thus, it remains to be determined how active Src can be evaluated in the clinical setting
from tumor biopsies. Therefore, we suggest that further studies of human HCC mTOR and
Src expression are required, prior to trialing a combinatorial strategy.
Our data also shed caution on choosing the correct experimental design in validating HCC
inhibitors. While in vitro the combined action of Rapamycin and Dasatinib on A52 prolifera-
tion was no better than that observed with Rapamycin alone, and yet in vivo the combinatorial
approach was very effective and suggests that it may limit other tumor functions. Additionally,
in preliminary experiments where Rapamycin treatment was given to mice with small A52
tumors, the inhibition of tumor growth was robust, but in larger established tumors of 500
mm3, Rapamycin had an initial response, but overtime the tumors increased resistance. These
data suggest, that perhaps when considering HCC therapeutic experiments in mice, larger syn-
geneic tumors should be used, to better reflect established immune cell, vascular and stromal
effectors, as seen in HCC patients.
Due to the high and growing rates of obesity and of the different cancer types, HCC demon-
strates perhaps the greatest increase in risk [39]. Significantly, serum APN levels are directly
and inversely associated with an increasing adipocyte mass and is a key player in the pathogen-
esis of type 2 diabetes, metabolic syndrome and NASH. Studies have shown that low serum
adiponectin is associated with progression to chronic liver disease [40, 41]. Given that previous
studies have observed APN KO mice to develop HCC after chemical insults [20, 21, 42], we
chose to use the liver carcinogen DEN to more accurately gauge the role of APN in HCC
growth. As expected, all WT and KO mice generated liver tumors without fibrosis. This could
reflect emerging data demonstrating that up to 50% of NASH HCC develops in the absence of
advanced fibrosis and inflammation [43–45]. Interestingly, while no difference was observed
in the number of tumors, there was marked anisokaryosis, earlier appearance, increased Ki67
staining and greater tumor volumes, indicating that the APN KO HCCs are more aggressive
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than WT. Moreover, due to numerous metabolic and tumor studies, it was our expectation
that APN absence would coincide with active AMPK/mTOR signaling in APN KO HCCs [16].
Published data concerning the manner through which APN inhibits HCC growth is divergent,
probably due to the utilization of human HCC cell lines and nude mouse models. By example,
Saxena et al., inoculated mice with HepG2 cancer cells and in this context, over-expression of
APN impeded HCC growth through JNK and mTOR [25]. In contrast, our analyses revealed
unaltered JNK, AKT, Src and AMPK/mTOR pathway activity. Given this data, and that the
tumors in the APN KO mice presented with unaltered markers of metabolism and inflamma-
tion, it suggests that other mechanisms promote APN KO tumor growth; and these we are
now investigating.
To generate primary cultures of HCC cells we utilized similar protocols from other cancer
biology fields, and pre-plating to remove fibroblasts [24, 46]. Of the seven tumors dissociated,
they all expressed the mTOR and Src pathways, markers of hepatocytes; albumin and AFP;
and epithelial markers; keratins. Only A52 cells gave reproducible growth in vitro and in vivo
and the pathology of the original A52 and transplanted tumors was similar. It remains to be
determined what genetic events drive A52 tumorgenicity and how further passaging through
mice and in culture will alter their tumorigenesis.
Taken together, we have established a new murine model of human HCC in the context of
reduced serum APN. Using this model, we illustrate that the combinatorial targeting of mTOR
and Src with the approved drugs Rapamycin and Dasatinib restricts growth in vivo, and in
considering human HCC we find activity of these pathways. Whilst the underlying molecular
mechanisms as to how Src and mTOR regulate each other’s function remains to be deter-
mined, our data suggests that this targeted combination effectively reduces tumor growth and
thus should be explored for the treatment of HCC.
Supporting information
S1 Fig. APN KO tumors have increased tumor cell proliferation and there is no hepatic
fibrosis. Representative Ki67 staining of A, WT (n = 6 mice) and B, APN KO (n = 6 mice)
tumor sections, and C, percentage (%) of Ki67 positive cells per field (p = 0.0044, by t-test).
Examples of Sirius red staining from WT and APN KO livers, illustrating limited hepatic fibro-
sis in both genotypes. Scale bar 250 μm.
(TIF)
S2 Fig. APN KO have unaltered signaling, metabolic, injury and inflammatory markers.
Serum evaluations reveled no differences between genotypes of A, glucagon; B, insulin; C, lep-
tin; D, IL-6; E, TNFα; F, AST; G, ALT; and by qPCR for the tumor inflammatory markers H,
IL-6, I, TNFα, and J, CD68. Active JNK is not associated with APN KO HCC growth. K and L,
Western blot and densitometry analyses show unaltered p-JNK/JNK protein in WT and APN
KO livers and tumors.
(TIF)
S3 Fig. Original Western blots for Fig 1.
(TIF)
S4 Fig. Original Western blots for Fig 2.
(TIF)
S5 Fig. Original Western blots for Fig 4.
(TIF)
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S6 Fig. Examples of PH3H and TUNEL staining from A52 tumors treated as placebo or
with Rapamycin and Dasatinib. Frozen sections were stained for PH3H (A) or TUNEL (B)
(green) and counterstained with DAPI (blue). Images 40x magnification.
(TIF)
S7 Fig. Original Western blots for Fig 5.
(TIF)
S8 Fig. Original Western blots for Fig 6.
(TIF)
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